Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis

Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant treatment were controversial and conflicting. We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzo, Alessandro, Cusmai, Antonio, Massafra, Raffaella, Bove, Samantha, Comes, Maria Colomba, Fanizzi, Annarita, Rinaldi, Lucia, Acquafredda, Silvana, Gadaleta-Caldarola, Gennaro, Oreste, Donato, Zito, Alfredo, Giotta, Francesco, Lorusso, Vito, Palmiotti, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221459/
https://www.ncbi.nlm.nih.gov/pubmed/35740985
http://dx.doi.org/10.3390/cells11121857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221459/
https://www.ncbi.nlm.nih.gov/pubmed/35740985
http://dx.doi.org/10.3390/cells11121857

Ejemplares similares